Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.
Press releases published on May 1, 2025
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
GlobeNewswire
·
May 1, 2025
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and …
Beta Bionics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 1, 2025
IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care …
Spur Therapeutics to Participate in Citizens JMP 2025 Life Sciences Conference
GlobeNewswire
·
May 1, 2025
LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that Chief Executive Officer Michael Parini will present a corporate overview at the Citizens JMP 2025 Life Sciences Conference being held May 7-8, 2025 in New York. The …
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
GlobeNewswire
·
May 1, 2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36- …
electroCore’s Truvaga™ Now Works with the Apple Health app
GlobeNewswire
·
May 1, 2025
ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. …
Neurogen Announces Partnership with NeuroX, a subsidiary of American TelePhysicians
GlobeNewswire
·
May 1, 2025
CHICAGO, May 01, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking announced it is partnering with NeuroX, a venture of American TelePhysicians, to provide virtual neurology services that help guide the patient journey on its brain health care ecosystem. …
New Clinical Data Presented about VIVO at the 46th Annual Heart Rhythm Association Conference
GlobeNewswire
·
May 1, 2025
FORT MILL, S.C., May 01, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that new …
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
GlobeNewswire
·
May 1, 2025
BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious …
HealthLynked Expands Patient Access with Enhanced Booking Options and Provider Reviews
GlobeNewswire
·
May 1, 2025
NAPLES, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp (OTCQB: HLYK) today announced a major enhancement to its appointment booking capabilities, further expanding patient access to care across its growing network of healthcare …
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
GlobeNewswire
·
May 1, 2025
- Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - …
Sotera Health Reports First-Quarter 2025 Results
GlobeNewswire
·
May 1, 2025
Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basis Q1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024 Q1 2025 …
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
GlobeNewswire
·
May 1, 2025
HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today …
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
GlobeNewswire
·
May 1, 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial …
Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025
GlobeNewswire
·
May 1, 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating …
SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results
GlobeNewswire
·
May 1, 2025
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on …
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
GlobeNewswire
·
May 1, 2025
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2025 …
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
GlobeNewswire
·
May 1, 2025
GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the …
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
GlobeNewswire
·
May 1, 2025
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking …
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
GlobeNewswire
·
May 1, 2025
BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track
GlobeNewswire
·
May 1, 2025
VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) reports on its year end 2024 and In the year ended December 31, 2024 revenue increased by 37% year over year to $4,785,711 and …